International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 023-027
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Usefullness of Serum Insulin-Like Growth Factor (IGF-1) and Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) for Colorectal Cancer Diagnosis
Ömer YILMAZ1, İrfan KORUK2, Kerim ÇAYIR3, Mehmet KORUK4, Arif YILMAZ5
1Atatürk University, Faculty of Medicine, Department of Gastroenterology, ERZURUM
2Av. Cengiz Gökcek State Hospital, Department of Gastroenterology, GAZİANTEP
3Atatürk University, Faculty of Medicine, Department of Medical Oncology, ERZURUM
4Gaziantep University, Faculty of Medicine, Department of Gastroenterology, GAZİANTEP
5Rize University, Faculty of Medicine, Department of Gastroenterology, RİZE
Keywords: Colorectal cancer, IGF-I, IGFBP-3, CEA, CA 19-9
Insulin-like growth factor (IGF-1) is a potent mitogen and an anti-apoptotic agent which is regulated by insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 carries IGF-1 through the bloodstream to the target tissues and protects it from proteolytic degradation. IGFBP-3 reduces tumorigenic potential of colon cancer cells in vitro. IGFBP- 3 may inhibit target cells directly. In the present study, we assessed whether serum levels of IGF-I and IGFBP-3 could be used as tumor markers in patients with colorectal cancers and evaluated its relationship with known tumor markers, carcinoembryogenic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
Our study enrolled 40 patients diagnosed with colorectal cancer histopathologically and 40 completely healthy, agematched subjects (control group). Serum IGF-I levels were found significantly higher in patients with colorectal cancers compared to control group (p< 0.01). Serum IGFBP-3 levels were significantly lower in patients with colorectal cancers compared to control group (p< 0.05). The observed increase in CEA and CA19-9 levels in the same subjects were found statistically significantly higher compared to control group (p< 0.05). However, no significant association could be found between change in IGF-1 and IGFBP-3 levels and CEA or CA 19-9. Increased serum levels of IGFI might be considered as a significant predictor of tumor presence in patients with suspected colorectal cancer. Agents that could increase IGFBP-3 levels might be promising for the treatment of colorectal cancers.
Ömer YILMAZ1, İrfan KORUK2, Kerim ÇAYIR3, Mehmet KORUK4, Arif YILMAZ5
1Atatürk University, Faculty of Medicine, Department of Gastroenterology, ERZURUM
2Av. Cengiz Gökcek State Hospital, Department of Gastroenterology, GAZİANTEP
3Atatürk University, Faculty of Medicine, Department of Medical Oncology, ERZURUM
4Gaziantep University, Faculty of Medicine, Department of Gastroenterology, GAZİANTEP
5Rize University, Faculty of Medicine, Department of Gastroenterology, RİZE
Keywords: Colorectal cancer, IGF-I, IGFBP-3, CEA, CA 19-9
Insulin-like growth factor (IGF-1) is a potent mitogen and an anti-apoptotic agent which is regulated by insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 carries IGF-1 through the bloodstream to the target tissues and protects it from proteolytic degradation. IGFBP-3 reduces tumorigenic potential of colon cancer cells in vitro. IGFBP- 3 may inhibit target cells directly. In the present study, we assessed whether serum levels of IGF-I and IGFBP-3 could be used as tumor markers in patients with colorectal cancers and evaluated its relationship with known tumor markers, carcinoembryogenic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
Our study enrolled 40 patients diagnosed with colorectal cancer histopathologically and 40 completely healthy, agematched subjects (control group). Serum IGF-I levels were found significantly higher in patients with colorectal cancers compared to control group (p< 0.01). Serum IGFBP-3 levels were significantly lower in patients with colorectal cancers compared to control group (p< 0.05). The observed increase in CEA and CA19-9 levels in the same subjects were found statistically significantly higher compared to control group (p< 0.05). However, no significant association could be found between change in IGF-1 and IGFBP-3 levels and CEA or CA 19-9. Increased serum levels of IGFI might be considered as a significant predictor of tumor presence in patients with suspected colorectal cancer. Agents that could increase IGFBP-3 levels might be promising for the treatment of colorectal cancers.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |